A Phase I Dose Escalation of MK0457 [VX 680, tozasertib] in Combination With Dasatinib in Patients With Chronic Myelogenous Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Trial Profile

A Phase I Dose Escalation of MK0457 [VX 680, tozasertib] in Combination With Dasatinib in Patients With Chronic Myelogenous Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Suspended
Phase of Trial: Phase I

Latest Information Update: 22 Apr 2014

At a glance

  • Drugs Dasatinib (Primary) ; Tozasertib (Primary)
  • Indications Acute lymphoblastic leukaemia; Chronic myeloid leukaemia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Merck & Co
  • Most Recent Events

    • 19 Nov 2007 Status changed from initiated to suspended.
    • 10 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top